Correction: Billeaud et al. “Effects on Fatty Acid Metabolism of a New Powdered Human Milk Fortifier Containing Medium-Chain Triacylglycerols and Docosahexaenoic Acid in Preterm Infants” Nutrients 2018, 10, 690
,
,
,
,
,
,
,
,
and
1
CIC Pédiatrique 1401 CHU, 33000 Bordeaux, France
2
ITERG, Université de Bordeaux, 33076 Bordeaux, France
3
Nestlé Health Sciences, 1066 Epalinges, Switzerland
4
Nestlé Research Centre, 1000 Lausanne, Switzerland
The authors wish to make a correction to the published version of their paper []. While replying to a Letter to the Editor [], we re-examined our results and realized that an erroneous version of Table 4 had been accidentally incorporated into the paper. During the manuscript review process, we were asked to reorder the table columns, include the standard deviations, and include all of the p values. Due to the substantial nature of these edits, many errors were accidentally introduced into this table. We sincerely apologize for this unfortunate error and regret any subsequent confusion. A corrected version of Table 4 is below.
Table 4 (Corrected).
Fatty acid profile (g/100 g of fatty acids) of total plasma phospholipids in preterm infants, receiving human milk fortified with a control (cHMF) or with a new human milk fortifier (nHMF) before and after 21 days of treatment. Estimates of the treatment effect nHMF/cHMF (difference) and the two-sided p-values are given for each fatty acid analyzed in the different lipid compartments.
This change does not impact the overall results or scientific conclusions. The original manuscript will remain online on the article webpage, with a reference to this correction.
References
Billeaud, C.; Boué-Vaysse, C.; Couëdelo, L.; Steenhout, P.; Jaeger, J.; Cruz-Hernandez, C.; Ameye, L.; Rigo, J.; Picaud, J.C.; Saliba, E.; et al. Effects on fatty acid metabolism of a new powdered human milk fortifier containing medium-chain triacylglycerols and docosahexaenoic acid in preterm infants. Nutrients2018, 10, 690. [Google Scholar] [CrossRef] [PubMed]
Bernhard, W.; Poets, C.F.; Franz, A.R. Letter to the Editor Re: Billeaud et al. Nutrients 2018, 10, 690. Nutrients2019, 11, 103. [Google Scholar] [CrossRef] [PubMed]
Table 4 (Corrected).
Fatty acid profile (g/100 g of fatty acids) of total plasma phospholipids in preterm infants, receiving human milk fortified with a control (cHMF) or with a new human milk fortifier (nHMF) before and after 21 days of treatment. Estimates of the treatment effect nHMF/cHMF (difference) and the two-sided p-values are given for each fatty acid analyzed in the different lipid compartments.
Table 4 (Corrected).
Fatty acid profile (g/100 g of fatty acids) of total plasma phospholipids in preterm infants, receiving human milk fortified with a control (cHMF) or with a new human milk fortifier (nHMF) before and after 21 days of treatment. Estimates of the treatment effect nHMF/cHMF (difference) and the two-sided p-values are given for each fatty acid analyzed in the different lipid compartments.
cHMF (n = 21)
nHMF (n = 26)
Baseline
After 21 Days
Baseline
After 21 Days
Difference
p Value
Mean
SD
Mean
SD
Mean
SD
Mean
SD
14:0
0.21
0.14
0.22
0.14
0.24
0.13
0.26
0.13
0.184
0.500
15:0
0.13
0.10
0.18
0.26
0.14
0.08
0.12
0.03
−0.071
0.722
16:0
25.00
5.55
22.75
6.21
26.00
3.58
26.46
2.76
0.180
0.020
16:0 DMA
0.63
0.18
0.70
0.17
0.64
0.16
0.74
0.27
−0.134
0.394
16:1 n-7
1.24
0.71
1.05
1.19
1.28
0.69
0.93
0.70
0.209
0.188
16:1 n-9
0.32
0.14
0.24
0.15
0.30
0.12
0.25
0.13
0.219
0.117
18:0
14.99
2.90
17.25
4.15
14.51
1.65
15.84
1.63
−0.060
0.203
18:0 DMA
0.33
0.12
0.47
0.37
0.35
0.10
0.36
0.14
−0.402
0.040
18:1 DMA
0.29
0.14
0.32
0.11
0.30
0.09
0.30
0.13
−0.288
0.054
18:1 n-7
3.07
0.59
2.36
0.62
3.05
0;89
2.59
0.77
0.122
0.015
18:1 n-9
14.04
2.16
11.98
3.37
13.90
3.03
12.45
2.97
0.051
0.286
trans-18:1
0.30
0.15
0.42
0.16
0.39
0.13
0.40
0.17
−0.112
0.515
18:2 n-6 (LA)
12.90
3.20
14.60
2.53
14.03
2.75
14.69
2.55
0.043
0.452
18:3 n-3 (ALA)
0.18
0.14
0.11
0.05
0.18
0.10
0.17
0.08
0.219
0.125
18:3 n-6 (GLA)
0.22
0.07
0.17
0.06
0.22
0.06
0.16
0.04
0.030
0.689
20:0
0.36
0.29
0.40
0.31
0.38
0.21
0.41
0.18
0.011
0.945
20:1 n-9
0.25
0.08
0.31
0.09
0.27
0.10
0.36
0.12
0.156
0.072
20:2 n-6
0.47
0.13
0.67
0.46
0.51
0.11
0.53
0.10
−0.112
0.340
20:3 n-6 (DGLA)
3.79
0.89
4.04
1.05
3.46
0.72
3.45
0.68
−0.161
0.041
20:3 n-9
2.56
1.46
1.90
1.53
2.12
1.19
2.11
1.51
0.089
0.612
20:4 n-6 (ARA)
9.81
2.33
10.63
3.54
9.09
2.03
8.26
2.58
−0.211
0.015
20:5 n-3 (EPA)
0.84
0.48
0.70
0.25
0.88
0.32
0.97
0.28
0.318
0.006
22:0
0.46
0.39
0.53
0.53
0.53
0.33
0.57
0.27
0.110
0.567
22:1 n-9
0.05
0.03
0.05
0.03
0.05
0.02
0.05
0.02
0.048
0.676
22:4 n-6
0.46
0.17
0.49
0.29
0.40
0.13
0.35
0.10
−0.257
0.032
22:5 n-3 (n-3 DPA)
0.46
0.24
0.53
0.31
0.44
0.12
0.40
0.12
−0.217
0.037
22:5 n-6 (n-6 DPA)
0.49
0.19
0.53
0.25
0.45
0.25
0.50
0.22
−0.005
0.970
22:6 n-3 (DHA)
3.60
1.42
3.96
1.94
3.22
0.93
3.54
1.04
−0.050
0.575
24:0
0.39
0.29
0.53
0.80
0.48
0.28
0.43
0.18
−0.056
0.742
24:1 n-9
1.50
1.23
1.47
0.83
1.55
0.98
1.77
0.73
0.191
0.368
Data are presented as geometric mean and geometric standard deviation (SD). ALA, α-linolenic acid; ARA, arachidonic acid; DGLA, dihomo-γ-linolenic acid; DHA, docosahexaenoic acid; DMA, dimethyl acetal; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; GLA, γ-linolenic acid; LA, linoleic acid.
